Objectives We review the evidence for tranexamic acid (TXA) for the treatment and
prevention of bleeding caused by surgery, trauma and bleeding disorders. We highlight …

Background The CRASH-2 trial showed that tranexamic acid (TXA) administration reduces
mortality in bleeding trauma patients. However, the effect appeared to depend on how soon …

Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

Tranexamic acid (TXA) reduces blood loss by inhibiting the enzymatic breakdown of fibrin. It
is often used in surgery to decrease bleeding and the need for blood transfusion. In 2011 …

Objective To assess the effect of tranexamic acid on blood transfusion, thromboembolic
events, and mortality in surgical patients. Design Systematic review and meta-analysis. Data …

Background Traumatic brain injury (TBI) is commonly accompanied by intracranial bleeding
which can worsen after hospital admission. Tranexamic acid (TXA) has been shown to …

Background Worldwide, over 10 million people are killed or hospitalized because of
traumatic brain injury each year. About 90% of deaths occur in low-and middle-income …

There are about 310 million major surgical procedures performed each year worldwide, with
more than 4 million deaths within 30 days postoperatively 1. Nearly 8 million surgical …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical
procedures and improves survival rates in obstetric and trauma patients with severe …